This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RPL32 / Large ribosomal subunit protein eL32 · IHC design guide
Design Immunohistochemistry for RPL32
Plan RPL32 staining in paraffin sections around its cytoplasmic tissue pattern (HPA tissue IHC). Cerebral cortex neurons and pancreatic exocrine cells show high staining, while adipocytes are listed as undetected comparators (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
RPL32 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in tissue (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining in neuronal and exocrine glandular cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A06487-1) | |
| Positive control | Cerebral cortex+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA show medium consistency; verify with controls (HPA tissue IHC) | |
| Regulation | Expression regulation is not annotated (UniProt) | |
| Isoform / epitope | No annotated isoforms; mature chain spans 2–135 (UniProt) |
Section 1
Recommended RPL32 IHC & IF Protocols
The catalog antibody protocol uses heat-mediated EDTA pH 8.0 retrieval (datasheet A06487-1). One published RPL32 tissue microarray IHC protocol provides additional staining conditions (PMC7411337).
| Sample | Paraffin-embedded differentiated adenocarcinoma of the human rectum tissue; fixative not specified (datasheet A06487-1) |
| Fixation | Image fixative and duration unreported (datasheet A06487-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A06487-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06487-1) |
| Primary antibody | Rabbit anti-RPL32, 2-5 μg/ml (datasheet A06487-1) |
| Primary incubation | Overnight at 4 °C (datasheet A06487-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A06487-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | RPL32-positive staining in neuronal cells of cerebral cortex (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A06487-1); the published tissue microarray protocol does not specify retrieval (PMC7411337).
Section 2
What Is the Expected RPL32 Staining Pattern?
RPL32 is a cytoplasmic component of the large ribosomal subunit, with no annotated transmembrane segment (UniProt P62910). In paraffin section IHC, expect cytoplasmic staining in neuronal cells of cerebral cortex and exocrine glandular cells of pancreas, both scored High by HPA (HPA: tissue IHC). HPA describes general cytoplasmic expression, but its Enhanced tissue profile has medium agreement with RNA data and awaits external verification (HPA: tissue IHC).
| Cytoplasmic staining in cerebral cortex neurons or pancreatic exocrine cells. | This matches the expected compartment and the two High cell populations in HPA tissue IHC (UniProt P62910; HPA: High in cerebral cortex neurons and pancreatic exocrine cells). Judge the relevant cells, rather than treating every structure in the section as an equivalent control. |
| Predominantly nuclear, membranous, or extracellular staining with little cytoplasmic signal. | That distribution conflicts with UniProt's cytoplasmic annotation and HPA's general cytoplasmic IHC profile (UniProt P62910; HPA: tissue IHC). Review morphology and detection controls before interpreting it as RPL32; the supplied evidence does not establish those compartments as an expected IHC pattern. |
| Strong staining in adipocytes, ovarian follicle cells, or skeletal muscle myocytes. | HPA reports RPL32 as Not detected in those specific cell populations (HPA: tissue IHC). Check cell identity and a no-primary control for cross-reactivity or endogenous detection activity (general IHC practice). Not detected is an assay observation, not proof that every cell lacks RPL32. |
| Diffuse chromogen over cells and surrounding tissue, obscuring cell boundaries. | A uniform haze cannot establish the cytoplasmic, cell-specific pattern described by HPA (HPA: tissue IHC). Treat it as background until a no-primary control and detection-system check distinguish nonspecific signal from interpretable staining (general IHC practice). |
| No staining in cerebral cortex neurons or pancreatic exocrine cells. | Both are High examples in HPA tissue IHC, so a blank result warrants a technical check (HPA: High in both cell populations). Confirm that the expected cells are present, then check the catalog antibody's IHC-P conditions and detection controls (general IHC practice). HPA staining does not guarantee every specimen will be positive. |
💡Expected RPL32 appearanceCall the result concordant when chromogen is predominantly cytoplasmic in cerebral cortex neurons or pancreatic exocrine cells with clearly appreciable staining, consistent with HPA's High scores; dominant nuclear, membranous, or tissue-wide haze is discordant (UniProt P62910; HPA: tissue IHC).
| Which cells provide a useful positive reference? | Cerebral cortex neuronal cells and pancreatic exocrine glandular cells are High; adrenal gland glandular cells and bronchial respiratory epithelial cells are Medium (HPA: tissue IHC). Choose a reference with identifiable target cells and compare staining within those cells. HPA's low tissue RNA specificity does not make all cell types equally useful controls (HPA: RNA specificity). |
| How should an HPA negative be interpreted? | Adipocytes in adipose tissue and breast, ovarian follicle cells, skeletal muscle myocytes, and soft-tissue fibroblasts are Not detected in HPA tissue IHC (HPA: tissue IHC). These are cell-level observations, not universal tissue-negative claims. Use them to assess unexpected staining only when the named cell population is identifiable. |
| What does target structure support? | RPL32 has no annotated transmembrane segment or signal peptide; UniProt places it in the cytoplasm and annotates a mature chain spanning residues 2–135 (UniProt P62910). These facts support an intracellular interpretation. They do not specify an antibody epitope, retrieval condition, or fixation sensitivity. |
| How strong is the IHC pattern evidence? | HPA lists 2 rabbit polyclonal antibodies, HPA047501 and HPA051994, with Enhanced IHC validation (HPA: antibodies). The tissue profile also reports medium agreement between staining and RNA expression and pending external verification (HPA: tissue IHC). Use its cell-level pattern as a reference while retaining that qualification. |
| IF/ICC Q&A: where is RPL32 seen? | HPA reports mainly endoplasmic reticulum and cytosol localization in ICC-IF, with both locations approved (HPA: subcellular ICC-IF). This supports an intracellular IF expectation, while the paraffin IHC comparison remains HPA's general cytoplasmic tissue pattern (HPA: tissue IHC). ICC-IF images do not establish an IHC-P protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| High reference tissue is blank. | The expected cells may be absent from the field, or an IHC workflow step may have failed; HPA scores the named cells High (HPA: tissue IHC). | Locate neurons or pancreatic exocrine cells first. Then review the catalog antibody's IHC-P instructions, retrieval, dilution, and detection setup as general IHC checks; no RPL32-specific retrieval or fixation effect is supplied. |
| Only nuclei appear positive. | Nuclear dominance conflicts with the cytoplasmic pattern reported by UniProt and HPA (UniProt P62910; HPA: tissue IHC). Counterstain or nonspecific signal may complicate interpretation (general IHC practice). | Inspect a no-primary control and distinguish chromogen from counterstain. Reassess whether cytoplasmic signal is present in the HPA High cell populations (HPA: tissue IHC). |
| Adipocytes or skeletal muscle myocytes stain strongly. | HPA scores these cell populations Not detected, making strong signal discordant with its tissue IHC observations (HPA: tissue IHC). Cross-reactivity or detection background is possible. | Confirm cell identity and compare a no-primary control. Assess the pattern alongside a High reference population before assigning the signal to RPL32 (HPA: tissue IHC; general IHC practice). |
| Chromogen is diffuse across the section. | Diffuse background can mask cell boundaries and prevent comparison with HPA's general cytoplasmic profile (HPA: tissue IHC; general IHC practice). | Check the no-primary control and the blocking, washing, and detection steps as general IHC practice. Score RPL32 only where cellular localization can be judged. |
| Signal is weak in a chosen reference. | A Medium or Low HPA cell population provides a less conspicuous reference than a High population (HPA: tissue IHC); weak signal alone does not identify the failing step. | Check the precise cell population and its HPA level. Compare cerebral cortex neurons or pancreatic exocrine cells, both High, before adjusting the IHC workflow (HPA: tissue IHC). |
| IHC looks cytoplasmic, but IF appears concentrated near the endoplasmic reticulum. | HPA reports general cytoplasmic tissue IHC and approved endoplasmic reticulum plus cytosol localization in ICC-IF (HPA: tissue IHC; HPA: subcellular ICC-IF). | Compare each result with its own assay's HPA description. An endoplasmic reticulum and cytosol IF pattern can coexist with a broader cytoplasmic chromogenic IHC appearance (HPA: subcellular ICC-IF; HPA: tissue IHC). |
Experiment evidence
IHC & IF images showing RPL32 staining
A06487-1 · IHCIHC analysis of RPL32 using anti-RPL32 antibody (A06487-1). RPL32 was detected in a paraffin-embedded section of differentiated adenocarcino
A06487-1 · IHCIHC analysis of RPL32 using anti-RPL32 antibody (A06487-1). RPL32 was detected in a paraffin-embedded section of human esophageal squamous c
A06487-1 · IFIF analysis of RPL32 using anti-RPL32 antibody (A06487-1). RPL32 was detected in an immunocytochemical section of MCF-7 cells. Enzyme antige
A06487-2 · IHCIHC analysis of RPL32 using anti-RPL32 antibody (A06487-2). RPL32 was detected in a paraffin-embedded section of human colorectal adenocarci
A06487-2 · IHCIHC analysis of RPL32 using anti-RPL32 antibody (A06487-2). RPL32 was detected in a paraffin-embedded section of human breast cancer tissue.
A06487-2 · IFIF analysis of RPL32 using anti-RPL32 antibody (A06487-2). RPL32 was detected in an immunocytochemical section of Hela cells. Enzyme antigen
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000144713-RPL32/tissue/cerebral+cortex#imid_14440416
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000144713-RPL32/tissue/colon#imid_14440326
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000144713-RPL32/tissue/liver#imid_14440343
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000144713-RPL32/tissue/pancreas#imid_14440294
HPA · ICC-IF MCF-7Human Protein Atlas immunofluorescence, MCF-7, antibody HPA051994; green = RPL32, blue = nucleus, red = microtubules.
HPA · ICC-IF MCF-7Human Protein Atlas immunofluorescence, MCF-7, antibody HPA051994; green = RPL32, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for RPL32 IHC & IF
🧪Run cerebral cortex first; neuronal cells should show strong staining (HPA: High in neuronal cells). Use adipose tissue as the negative tissue, where adipocytes are not detected (HPA: Not detected in adipocytes); within the cortex, cells without neuronal cytoplasmic staining should remain at background, but the supplied HPA rows do not establish a specific internal cell type as RPL32-negative (HPA: cerebral cortex neuronal cells High; UniProt: Cytoplasm).
Positive control tissue: Cerebral cortex (Neuronal cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show RPL32 in MCF-7, PC-3, U2OS, with annotated localisation: Endoplasmic reticulum (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and concentration-matched nonimmune rabbit IgG isotype controls, plus an RPL32-knockout biological negative if available (caption: rabbit anti-RPL32; standard IHC controls). For cortical DAB staining, quench endogenous peroxidase and check neuronal pigment; for IF, check autofluorescence (standard IHC/IF practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected A06487-1 paraffin-section caption does not state the fixative (caption: fixative not stated). That caption uses heat-mediated EDTA retrieval at pH 8.0 and 2 μg/ml primary overnight at 4°C, but does not establish that retrieval is required (caption: IHC conditions). The supplied evidence does not establish whether frozen sections or IF are easier; cortical neuronal lipofuscin can complicate DAB scoring and IF interpretation (HPA: ICC-IF images; standard IHC/IF practice).
HPA tissue IHC evidence for RPL32
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Pancreas | Exocrine glandular cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Ovary | Follicle cells | Not detected | Protein (IHC) | HPA → |
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
| Soft tissue | Fibroblasts | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced RPL32 IHC Tips
Troubleshoot RPL32 staining in paraffin sections by checking retrieval, compartment, controls and scoring against the reported IHC pattern.
What should I change when RPL32 staining is weak after antigen retrieval?
Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet A06487-1). The selected paraffin-section example used this retrieval, followed by 10% goat serum block and 2 μg/ml primary antibody overnight at 4°C (datasheet A06487-1). If staining remains weak, compare a second retrieval condition on adjacent sections while holding antibody concentration and detection constant, and inspect tissue integrity before choosing a condition (standard IHC practice). Judge improvement by stronger cellular cytoplasmic staining without a parallel rise in diffuse background; cytoplasmic expression is the reported tissue pattern (HPA tissue IHC).
How can I troubleshoot fixation-related loss of RPL32 staining?
Target-specific fixation sensitivity is unknown because the selected paraffin-section caption does not state a fixative (datasheet A06487-1). Record each specimen's fixative, fixation duration and processing history, then compare similarly processed sections under the same retrieval and detection conditions (standard IHC practice). Include a concurrently stained section with established RPL32 cytoplasmic staining, such as the reported rectal adenocarcinoma example, to distinguish a run failure from specimen variation (datasheet A06487-1; HPA tissue IHC). If only one processing batch stains poorly, assess morphology and repeat staining with consistent section handling before attributing the loss to fixation (standard IHC practice).
How should I assess punctate or nuclear-looking RPL32 staining?
Assess whether signal remains predominantly cytoplasmic across intact cells, the general pattern reported in tissue IHC (HPA tissue IHC). RPL32 is a large ribosomal subunit component annotated in the cytoplasm, while cell imaging places it mainly in the endoplasmic reticulum and cytosol (UniProt P62910; HPA subcellular). Compare suspicious nuclear or isolated punctate signal with the counterstain, cell boundaries and adjacent well-preserved areas before scoring it as RPL32 (standard IHC practice). A changed staining pattern merits checks of retrieval, primary-antibody concentration and detection controls; compartment disagreement alone cannot establish a new biological localisation (standard IHC practice; HPA subcellular).
Could isoforms or epitope accessibility explain inconsistent RPL32 staining?
The supplied record annotates 0 isoforms and no transmembrane segment, so an isoform-specific staining explanation has no support here (UniProt P62910). RPL32 has annotated modified residues, including N6-succinyllysine at 50 and phosphoserine at 62, but the antibody epitope is unspecified (UniProt P62910; datasheet A06487-1). Do not assign a staining difference to either modification without epitope mapping or direct experimental evidence (standard IHC practice). Compare retrieval conditions and antibody titration on matched sections, then assess whether the expected cytoplasmic distribution becomes clearer without increased background (standard IHC practice; HPA tissue IHC).
How can IF help investigate an ambiguous chromogenic RPL32 pattern?
For a separate IF experiment, pair RPL32 with a validated marker for the cell type under study and assess colocalisation at single-cell resolution (standard IF practice). Choose fluorophores after examining unstained tissue in each channel, placing the weaker signal where autofluorescence is lowest and checking single-stain controls for bleed-through (standard IF practice). RPL32 is annotated without a transmembrane segment and is observed mainly in cytosol and endoplasmic reticulum, so test permeabilisation that permits access to intracellular epitopes without disrupting cell structure (UniProt P62910; HPA subcellular; standard IF practice). Because the antibody epitope is unspecified, optimise that access empirically rather than assuming an endoplasmic-reticulum membrane orientation (datasheet A06487-1; standard IF practice).
What should I check when the DAB background obscures RPL32 staining?
First compare the stained section with a primary-antibody omission control to locate signal produced by the detection system (standard IHC practice). The selected example uses biotinylated secondary antibody, a streptavidin–biotin complex and DAB, making detection-step controls useful when staining appears outside cells (datasheet A06487-1; standard IHC practice). Check the peroxidase block, serum block, washes and DAB development, and examine whether background concentrates at tissue edges or damaged regions (standard IHC practice). Titrate the 2 μg/ml primary-antibody starting condition if background persists, while retaining an internal reference for the expected cytoplasmic pattern (datasheet A06487-1; HPA tissue IHC; standard IHC practice).
How should I quantify RPL32 staining across differently cellular sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region of interest before scoring, then exclude folds, necrosis and section edges using the same criteria throughout (standard IHC practice). For intact cells, record the percentage positive and an intensity-based H-score on the 0–300 scale; report the scoring thresholds and observer method (standard IHC practice). Normalise positive-cell counts to the number of eligible cells, or use positive-cell density per mm² of evaluable tissue when area is the comparison unit (standard IHC practice). Stratify by cell type because reported tissue staining ranges from high in cerebral-cortex neuronal cells to undetected in adipocytes, and keep acquisition and DAB development consistent (HPA tissue IHC; standard IHC practice).
When is an unexpected RPL32-positive area likely to be artefactual?
A convincing result has cellular cytoplasmic signal in preserved tissue, consistent with the reported general tissue pattern and RPL32 cytoplasmic annotation (HPA tissue IHC; UniProt P62910). Treat dominant nuclear staining, signal restricted to necrosis or section edges, and deposits lacking cell boundaries as reasons to investigate artefact (standard IHC practice; HPA tissue IHC). Compare the suspected cell type with reported observations: neuronal cells in cerebral cortex stain highly, whereas adipocytes were not detected in the cited tissue survey (HPA tissue IHC). Check a primary-antibody omission control for endogenous enzyme or detection signal, and weigh biological claims cautiously because tissue staining has medium RNA consistency and awaits external verification (standard IHC practice; HPA tissue IHC).
Boster reagents
Best RPL32 / Large ribosomal subunit protein eL32 IHC Antibodies
Both antibodies have human paraffin-section IHC and cell-based IF images (image captions: A06487-1, A06487-2); Human, Mouse, and Rat are listed as reactive species (catalog: reactivity).
Real IHC data
Anti-RPL32 Antibody ®
Cat # A06487-1
Real IHC data
Anti-RPL32 Antibody ®
Cat # A06487-2
A06487-1 has IHC images from human rectal adenocarcinoma, esophageal squamous carcinoma, tonsil, and renal-pelvis squamous metaplasia, plus IF in MCF-7 cells (image captions: A06487-1). A06487-2 has IHC images from human colorectal, breast, and endometrial cancers and esophageal squamous carcinoma, plus IF in HeLa cells and a human breast-cancer section (image captions: A06487-2).
Which to pick: For paraffin-section chromogenic IHC, start with A06487-1 if its stated 2–5 μg/ml range is useful; its own IHC captions document EDTA pH 8.0 retrieval and DAB detection, but do not report the fixative (catalog: A06487-1 IHC dilution; IHC captions: A06487-1). For IF/ICC, consider A06487-2 when tissue IF is needed: its own captions show cell-based IF and paraffin-section IF, while A06487-1 has cell-based IF; both list IF and ICC, and clonality is unreported (catalog: applications and clone fields; IF captions: A06487-1, A06487-2). Both list Human, Mouse, and Rat reactivity, but the supplied IHC and IF images document human samples only, so verify performance in mouse or rat samples (catalog: reactivity; image captions: A06487-1, A06487-2).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P62910 (RL32_HUMAN, Large ribosomal subunit protein eL32).
- Human Protein Atlas. RPL32 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. RPL32 subcellular location (ICC-IF): Mainly localized to the endoplasmic reticulum and cytosol..
- Human Protein Atlas. RPL32 antibody validation summary (2 antibodies).
- Enhanced regenerative and developmental potential of embryonal and stem cell-derived platelets compared to adult platelets. Cell reports. Medicine 2025 — PMC12432385.
- Biological effect of ribosomal protein L32 on human breast cancer cell behavior. Molecular medicine reports 2020 — PMC7411337.
- RPL32 Promotes Lung Cancer Progression by Facilitating p53 Degradation. Molecular therapy. Nucleic acids 2020 — PMC7281510.
- PubMed PMID:3866218 — UniProt-cited evidence.
- PubMed PMID:11875025 — UniProt-cited evidence.
- PubMed PMID:15498874 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for RPL32 (Large ribosomal subunit protein eL32). Expected localisation Cytoplasmic staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A06487-1). Validated IHC antibody: A06487-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebral cortex (Neuronal cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded differentiated adenocarcinoma of the human rectum tissue; fixative not specified…; 2. Fixation: Image fixative and duration unreported (datasheet A06487-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A06487-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06487-1); 8. Primary antibody: Rabbit anti-RPL32, 2-5 μg/ml (datasheet A06487-1); 9. Primary incubation: Overnight at 4 °C (datasheet A06487-1). Watch for: Fixation: Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining and RNA show medium consistency; verify with controls (HPA tissue IHC); Isoform / epitope: No annotated isoforms; mature chain spans 2–135 (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt P62910, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the endoplasmic reticulum and cytosol., Datasheet A06487-1, PMC7411337. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/RPL32/immunohistochemistry-ihc-guide.